Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Budamanon May 11, 2022 7:38am
213 Views
Post# 34673176

RE:RE:Great News!

RE:RE:Great News!I am one of these "old investors" that you mentioned. Why would I sell any of my shares to exercise my warrants at this moment in time? The company has all of the data AND the algorithm key in their possession from the trials. This stock is about to jump to between $2 and $3 per share with the results, followed by $3 to $7 per share when Phase 3 is announced. They will be bought out for over $20 per share by a large Pharma company during Phase 3. I will exercise my warrants when Phase 3 begins, unless HEM accelerates them before that point in time. This is a terrible soft bash and is almost as bad as the one about study publishing timeframes. If you are a shorter, cover soon or you will lose everything. Good luck everyone! In my opinion only. Thanks-Buda.
<< Previous
Bullboard Posts
Next >>